{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:05:16Z","timestamp":1779876316316,"version":"3.53.1"},"reference-count":6,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psoriasis and Psoriatic Arthritis\u00ae"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>In this commentary, we discuss the role of pharmacy benefit managers (PBMs) on access to biologics for patients with psoriasis. We highlight structural and system level barriers to biologics access, as well as how PBMs work as intermediaries between insurers, pharmacies, and drug manufactures to influence prescription formularies and generate health savings. We also discuss how controversial PBM practices such as step therapy, prior authorizations, and spread pricing may limit access to biologics and potentially increase cost for patients. Finally, we highlight how dermatologists and national organizations such as the National Psoriasis Foundation can collaborate and advocate for legislative reforms to increase transparency among PBMs.<\/jats:p>","DOI":"10.1177\/24755303251387126","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:28:22Z","timestamp":1761128902000},"page":"97-98","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The Role of Pharmacy Benefit Managers in Access to Biologics for Dermatologic Conditions"],"prefix":"10.1177","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9223-2380","authenticated-orcid":false,"given":"Melissa C.","family":"Leeolou","sequence":"first","affiliation":[{"name":"Stanford University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin L.","family":"Jia","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Harris","sequence":"additional","affiliation":[{"name":"National Psoriasis Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7883-6439","authenticated-orcid":false,"given":"Wilson","family":"Liao","sequence":"additional","affiliation":[{"name":"University of California San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0153-2"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmp2309533"},{"key":"e_1_3_3_4_2","volume-title":"The Top Pharmacy Benefit Managers of 2023: Market Share and Trends for the Biggest companies-and What\u2019s Ahead","author":"Fein AJ","year":"2024","unstructured":"Fein AJ. The Top Pharmacy Benefit Managers of 2023: Market Share and Trends for the Biggest companies-and What\u2019s Ahead. Drug Channels; 2024. https:\/\/www.drugchannels.net\/2024\/04\/the-top-pharmacy-benefit-managers-of.html"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.063"},{"key":"e_1_3_3_6_2","volume-title":"FTC Releases Second Interim Staff Report on Prescription Drug Middlemen","author":"Dad TK","year":"2025","unstructured":"Dad TK, Nguyen ST. FTC Releases Second Interim Staff Report on Prescription Drug Middlemen. Federal Trade Commission; 2025. https:\/\/www.ftc.gov\/news-events\/news\/press-releases\/2025\/01\/ftc-releases-second-interim-staff-report-prescription-drug-middlemen"},{"key":"e_1_3_3_7_2","unstructured":"Ohio Auditor of State. Auditor\u2019s report: pharmacy benefit managers take fees of 31% on generic drugs worth $208M in one-year period. 2018. https:\/\/ohioauditor.gov\/news\/pressreleases\/Details\/5042"}],"container-title":["Journal of Psoriasis and Psoriatic Arthritis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24755303251387126","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24755303251387126","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24755303251387126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T09:41:27Z","timestamp":1779874887000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24755303251387126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/24755303251387126"],"URL":"https:\/\/doi.org\/10.1177\/24755303251387126","relation":{},"ISSN":["2475-5303","2475-5311"],"issn-type":[{"value":"2475-5303","type":"print"},{"value":"2475-5311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]}}}